10 results about "Disintegrin" patented technology

Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange / hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration / diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (a disintegrin and metalloproteinase with thrombospondin motif 12 protein) in the pathogenesis of chronic kidney and heart diseases, and in particular chronic renal insufficiency and renal fibrosis, and heart failure and cardiac fibrosis, respectively. The present invention further relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, as well as pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active substances that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

Disclosed are methods and systems for the analysis activity of enzyme disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) in a sample. The methods and systems disclosed herein can be useful for diagnosis of thrombotic thrombocytopenic purpura in a patient.

The invention provides methods for treating conditions of immune disfunction, such as rheumatoid arthritis (RA), using enzyme- and substrate-selective exosite inhibitors of A disintegrin and metalloprotease 10 (ADAM10), such as N-(3-chloro-4-methylphenyl)-2-[2-(3-methoxybenzoyl) hydrazinyl]-2-oxoacetamide (PubChem CID3117694). The method for treating a condition of immune disfunction in a subject in need thereof includes: providing a composition including a therapeutically effective dosage of a modulator of A disintegrin and metalloprotease 10 (ADAM10) and at least one acceptable pharmaceutical carrier; and administering the composition to the subject, thereby treating the condition of immune disfunction in the subject by modulating ADAM10. A composition including a therapeutically effective dosage of a modulator of A disintegrin and metalloprotease 10 (ADAM10), a therapeutically effective dosage of indomethacin, and at least one acceptable pharmaceutical carrier is for use in treating a condition of immune disfunction or inflammation in a subject in need thereof.

The present invention relates to the interaction of the protein HMCN1 (hemicentin 1 or fibulin 6) as a substrate of the protease ADAMTS12 (A disintegrin and metalloproteinase with thrombospondin motifs 12-protein) in the pathogenesis of chronic kidney and heart diseases and in particular chronic renal insufficiency and renal fibrosis or cardiac insufficiency and cardiac fibrosis. The present invention relates to methods for identifying compounds that bind to and / or inhibit the protease ADAMTS12, and to pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active ingredients that inhibit the cleavage and digestion of hemicentin 1 by the metalloprotease ADAMTS12 or the interaction of hemicentin 1 with ADAMTS12.

The disclosure provides a method for treating and / or preventing graft rejection with A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member-13 (ADAMT S13). The disclosure provides a method for increasing ADAMTS13-mediated von Willebrand factor (VWF) cleavage in a subject that received a graft by administering ADAMTS13. The disclosure also provides a method of determining the likelihood that a subject will rejection a graft.

The present invention relates to the role of ADAMTS12 protein (A Disintegrin And Metalloproteinase with ThromboSpondin motifs 12 protein) in the development of chronic kidney disease, in particular progressive chronic kidney disease and renal fibrosis. In particular, the present invention relates to methods for identifying compounds that bind to the ADAMTS12 protein and to the use of ADAMTS12 protein for screening and identifying ADAMTS12-interacting and ADAMTS12-inhibiting compounds. The present invention further relates to pharmaceutical compositions for use in the treatment of kidney diseases, in particular pharmaceutical compositions comprising active agents that bind to and / or inhibit the ADAMTS12 protein.

Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange / hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration / diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.

The application relates to the field of biological medicine, in particular to a detection method and application of ophidiotoxin and vivero toad venom. (1) Antibodies obtained by immunizing a mixture of SVSP chimeras and Disintegrin chimeras and two kinds of antigens of 3FT chimeras can effectively identify ophidiotoxin and vivero toad venom; (2) Antibodies obtained by immunizing two kinds of antigens of multicinctus 3FT chimeras and Atra 3FT chimeras can effectively identify ophidiotoxin and silver ring snake venom; (3) The cation exchange chromatography method is used to enrich the snake venom in the sample, and the sensitivity of the to-be-detected snake venom in blood and tissue fluid is improved; (4) Standard samples of cobra and silver ring snake venom are established for the first time. Compared with the prior art, the method has the effects of identifying vivero toad venom and ophidiotoxin by searching for difference proteins, predicting linear antigen epitopes, removing the same and highly similar linear antigen epitopes and serially recombinantly expressing the linear antigen epitopes.